NFE2L2 and lung carcinoma: For example, lung cancers frequently harbour mutations in NFE2L2 (nuclear factor, erythroid 2-like 2, encodes for NRF2) or KEAP1 (encodes for KEAP1, a negative regulator of NRF2), which results in the activation of antioxidant pathways, including SLC7A11 and NQO1 upregulation [26,27].